Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341580 | 0.85 | PSMB11 (0.53) | EGLN1RAB9AMAPK8 | |
| SCHEMBL8002583 | 0.85 | ALDH1A1 (0.64) | MEN1KMT2AEGLN1FLT1GPR139 | |
| SCHEMBL29195069 | 0.83 | EGLN1 (0.46) | EGLN1RAB9A | |
| SCHEMBL12245344 | 0.83 | CDK1 (0.63) | MEN1KMT2ATDP1EGLN1VEGFA | |
| SCHEMBL9048413 | 0.82 | FADS1 (0.54) | EGLN1VEGFAFLT1GPR139CYP1A2 | |
| SCHEMBL21841256 | 0.82 | EGLN1 (0.55) | MEN1KMT2ATDP1EGLN1VEGFA | |
| SCHEMBL21841322 | 0.82 | EGLN1 (0.48) | KMT2AEGLN1USP5HDAC6AKR1B1 | |
| SCHEMBL12900998 | 0.82 | EGLN1 (0.57) | KMT2ATDP1EGLN1VEGFAFLT1 | |
| SCHEMBL15610498 | 0.82 | KDM4E (0.56) | MEN1KMT2ATDP1EGLN1USP5 | |
| SCHEMBL11380224 | 0.81 | POLB (0.64) | MEN1KMT2ATDP1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157749-B2 | Borate-based drug and use thereof | CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) | 2024-12-03 | — | — | US | disclosed |
| EP-3851108-B1 | BORATE-BASED DRUG AND USE THEREOF | CHENGDU ORIGIN BIOTECHNOLOGY LTD COMPANY (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-3851108-B1 | BORATE-BASED DRUG AND USE THEREOF | CHENGDU ORIGIN BIOTECHNOLOGY LTD COMPANY (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3851108-A1 | BORATE-BASED DRUG AND USE THEREOF | Chengdu Origin Biotechnology Limited Company (CN) | 2021-07-21 | — | — | EP | disclosed |
| EP-3851108-A1 | BORATE-BASED DRUG AND USE THEREOF | Chengdu Origin Biotechnology Limited Company (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020052488-A1 | BORATE-BASED DRUG AND USE THEREOF | 成都奥璟生物科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052488-A1 | BORATE-BASED DRUG AND USE THEREOF | 成都奥璟生物科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010068520-A2 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | PSMB11, PSMB1, PSMB3 | MEN1 1751/4885KMT2A 2153/4885TDP1 2213/4885 |
| US-12157749-B2 | Borate-based drug and use thereof | PSMB11, PSMB1, PSMB3 | MEN1 1751/4885KMT2A 2153/4885TDP1 2213/4885 |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CNR1, CNR2, HRH1 | MEN1 4697/4885KMT2A 3034/4885TDP1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.